Research Progress of Acquired Resistance Mediated by MET Amplification in Advanced Non-small Cell Lung Cancer
Mesenchymal-epithelial transition factor (MET) amplification is an important driver of resistance in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and the combination of MET proto-oncogene (MET) and EGFR-tyrosine kinase inhibitors (TKIs) has shown promise in over...
Main Authors: | Sisi PAN, Na WANG, Xia SONG |
---|---|
Format: | Article |
Language: | zho |
Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2022-08-01
|
Series: | Chinese Journal of Lung Cancer |
Subjects: | |
Online Access: | http://dx.doi.org/10.3779/j.issn.1009-3419.2022.102.23 |
Similar Items
-
Progress of c-MET Signaling Pathway and TKIs in Non-small Cell Lung Cancer
by: Xiaoqing YU, et al.
Published: (2017-04-01) -
Research Progresses in the Treatment of NSCLC with MET Gene Variants: A Riview
by: Ran CHEN, et al.
Published: (2022-12-01) -
Targeting <i>MET</i> Amplification: Opportunities and Obstacles in Therapeutic Approaches
by: Yuichi Kumaki, et al.
Published: (2023-09-01) -
MET Expression Level in Lung Adenocarcinoma Loosely Correlates with <i>MET</i> Copy Number Gain/Amplification and Is a Poor Predictor of Patient Outcome
by: Wei Yin, et al.
Published: (2022-05-01) -
Efficacy and Tolerability of ALK/MET Combinations in Patients With ALK-Rearranged Lung Cancer With Acquired MET Amplification: A Retrospective Analysis
by: Ibiayi Dagogo-Jack, MD, et al.
Published: (2023-08-01)